Delivery Order SPE2DR25D2014-SPE2DR26FA4H3
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on January 30, 2026, for CAPLYTA 42 mg capsules (30-count supply) with a ceiling value of $15,241.82. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of February 2, 2026, and represents a non-set-aside, competitively awarded procurement. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $3,372.23 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units) with a completion date of January 29, 2026. This non-competitive, firm fixed-price delivery order was issued on January 28, 2026, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a subsidiary of Cencora, Inc., a major pharmaceutical distributor serving federal healthcare...
- The Defense Logistics Agency awarded a Delivery Order valued at $6,163.49 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units) on January 22, 2026, with completion expected by January 23, 2026. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, operates as a subsidiary of Cencora, Inc. and serves as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $3,566.41 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units), with an ultimate completion date of October 31, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued competitively. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $7,874.08 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units) on January 8, 2026, with completion expected by January 9, 2026. This non-set-aside, competitively awarded contract utilizes firm fixed-price pricing and will be fulfilled from the contractor's Conshohocken, Pennsylvania location. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger...
- The Defense Logistics Agency awarded a delivery order valued at $7,731.06 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 21 mg capsules (30-count packaging) on December 18, 2025, with an ultimate completion date of December 19, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at...
- The Defense Logistics Agency awarded a delivery order valued at $3,351.92 to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units) on August 6, 2025, with an ultimate completion date of August 7, 2025. This is a firm fixed-price, non-set-aside contract to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $26,501.51 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units). This firm fixed-price contract, which was not set-aside and competitively awarded, was executed on December 8, 2025, with an ultimate completion date of December 9, 2025. The pharmaceuticals will be delivered to AmerisourceBergen's distribution center in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $3,018.19 to AmerisourceBergen Drug Corp on October 14, 2025, for the supply of CAPLYTA 42 mg capsules (30-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of October 15, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units) under a firm fixed-price contract valued at $10,226.69. The award was made on July 24, 2025, with an ultimate completion date of July 25, 2025, and represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery...
- SPE2DR25D2014Indefinite Delivery Contract
- SPE2DR25D2014-SPE2DR26FA4H3Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,931.19 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units) on February 2, 2026, with an ultimate completion date of February 3, 2026. This non-set-aside, competitively awarded contract employs firm fixed-price pricing and is performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at up to $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including medications across multiple therapeutic domains, vaccines, and medical devices. CAPLYTA, an atypical antipsychotic used in the treatment of schizophrenia and bipolar disorder, represents one of the specialized medications delivered through this prime vendor contract to support the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.9k | 2/1/26 |